Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

Journal of the American Academy of Dermatology

Volumn 75, Issue 3, 2016, Pages 494-503.e6

  Paller, Amy S ^a   Tom, Wynnis L ^b,c   Lebwohl, Mark G ^d   Blumenthal, Robin L ^e   Boguniewicz, Mark ^f,g   Call, Robert S ^h   Eichenfield, Lawrence F ^b,c   Forsha, Douglass W ⁱ   Rees, William C ^j   Simpson, Eric L ^k   Spellman, Mary C ^e   Stein Gold, Linda F ^l   Zaenglein, Andrea L ^m   Hughes, Matilda H ^e   Zane, Lee T ^e   Hebert, Adelaide A ⁿ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

^f DEPARTMENT OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h Clinical Research Partners   (United States)

ⁱ Jordan Valley Dermatology and Research Center   (United States)

^j Pi Coor Clinical Research   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l HENRY FORD HEALTH SYSTEM   (United States)

^m PENN STATE COLLEGE OF MEDICINE   (United States)

ⁿ UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

atopic dermatitis; crisaborole ointment; eczema; phosphodiesterase 4; pruritus; topical therapy

Indexed keywords

CRISABOROLE; BORON DERIVATIVE; DERMATOLOGICAL AGENT; FUSED HETEROCYCLIC RINGS; OINTMENT; PHOSPHODIESTERASE IV;

ADOLESCENT; ADULT; ADULT DISEASE; AGED; APPLICATION SITE BURNING; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTICLE; ATOPIC DERMATITIS; CHILD; CHILDHOOD DISEASE; COMPLICATION; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INJECTION SITE STINGING; INJURY; INTOXICATION; INVESTIGATOR STATIC GLOBAL ASSESSMENT SCORE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OINTMENT; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SKIN DISEASE; SKIN DISEASE ASSESSMENT; SOFT TISSUE DISEASE; STAPHYLOCOCCAL SKIN INFECTION; THORAX DISEASE; TOPICAL TREATMENT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; DERMATITIS, ATOPIC; MIDDLE AGED; PRESCHOOL CHILD; PRURITUS; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; BORON COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CHILD; CHILD, PRESCHOOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PRURITUS; YOUNG ADULT;

EID: 84996636605     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.05.046     Document Type: Article

References (45)

1. Bieber, T., Atopic dermatitis. Ann Dermatol 22 (2010), 125–137.
2. Bieber, T., Atopic dermatitis. N Engl J Med 358 (2008), 1483–1494.
3. Eichenfield, L.F., Tom, W.L., Berger, T.G., et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71 (2014), 116–132.
4. Odhiambo, J.A., Williams, H.C., Clayton, T.O., Robertson, C.F., Asher, M.I., Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol 124 (2009), 1251–1258.
5. Arkwright, P.D., Motala, C., Subramanian, H., Spergel, J., Schneider, L.C., Wollenberg, A., Management of difficult-to-treat atopic dermatitis. Journal of Allergy Clin Immunol Pract 1 (2013), 142–151.
6. Blume-Peytavi, U., Metz, M., Atopic dermatitis in children: management of pruritus. J Eur Acad Dermatol Venereol 26:Suppl 6 (2012), 2–8.
7. Mollanazar, N.K., Smith, P.K., Yosipovitch, G., Mediators of chronic pruritus in atopic dermatitis: getting the itch out?. Clin Rev Allergy Immunol, 2015 [Epub ahead of print].
8. Schneider, L., Tilles, S., Lio, P., et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 131 (2013), 295–299.
9. Ellis, C.N., Drake, L.A., Prendergast, M.M., et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 46 (2002), 361–370.
10. Margolis, J.S., Abuabara, K., Bilker, W., Hoffstad, O., Margolis, D.J., Persistence of mild to moderate atopic dermatitis. JAMA Dermatol 150 (2014), 593–600.
11. Carr, W.W., Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 15 (2013), 303–310.
12. Siegfried, E.C., Jaworski, J.C., Hebert, A.A., Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 14 (2013), 163–178.
13. Walling, H.W., Swick, B.L., Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol 3 (2010), 99–117.
14. Jimenez, J.L., Punzon, C., Navarro, J., Munoz-Fernandez, M.A., Fresno, M., Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 299 (2001), 753–759.
15. Baumer, W., Hoppmann, J., Rundfeldt, C., Kietzmann, M., Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 6 (2007), 17–26.
16. Grewe, S.R., Chan, S.C., Hanifin, J.M., Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 70 (1982), 452–457.
17. Heskel, N.S., Chan, S.C., Thiel, M.L., Stevens, S.R., Casperson, L.S., Hanifin, J.M., Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodiesterase activity in children with atopic parents. J Am Acad Dermatol 11 (1984), 422–426.
18. Butler, J.M., Chan, S.C., Stevens, S., Hanifin, J.M., Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol 71 (1983), 490–497.
19. Hanifin, J.M., Phosphodiesterase and immune dysfunction in atopic dermatitis. J Dermatol Sci 1 (1990), 1–6.
20. Hanifin, J.M., Chan, S.C., Cheng, J.B., et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 107 (1996), 51–56.
21. Moustafa, F., Feldman, S.R., A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J, 20, 2014, 22608.
22. Wittmann, M., Helliwell, P.S., Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb) 3 (2013), 1–15.
23. Jarnagin, K., Chanda, S., Coronado, D., et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol 15 (2016), 390–396.
24. Akama, T., Baker, S.J., Zhang, Y.K., et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 19 (2009), 2129–2132.
25. Dastidar, S.G., Rajagopal, D., Ray, A., Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 8 (2007), 364–372.
26. Freund, Y.R., Akama, T., Alley, M.R., et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett 586 (2012), 3410–3414.
27. Nazarian, R., Weinberg, J.M., AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 10 (2009), 1236–1242.
28. Jimenez, J.L., Iniguez, M.A., Munoz-Fernandez, M.A., Fresno, M., Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. Cell Signal 16 (2004), 1363–1373.
29. Zane, L.T., Chanda, S., Jarnagin, K., Nelson, D.B., Spelman, L., Stein Gold, L.F., Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Future Med 8 (2016), 853–866.
30. Zane, L.T., Kircik, L., Call, R., et al. AN2728 Topical ointment, 2% in patients 2 to 17 years of age with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure (MUSE) study. Pediatr Dermatol, 2016 [In press].
31. Murrell, D., Gebauer, K., Spelman, L., Zane, L.T., Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2A, vehicle-controlled, proof-of-concept study. J Drugs Dermatol 14 (2015), 1108–1112.
32. Stein Gold, L.F., Spelman, L., Spellman, M.C., Hughes, M.H., Zane, L.T., A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol 14 (2015), 1394–1399.
33. Tom, W.L., Van, S.M., Chanda, S., Zane, L.T., Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr Dermatol 33 (2016), 150–159.
34. Hanifin, J.M., Rajka, G., Diagnostic features of atopic dermatitis. Acta Dermatol Venereol 92:Suppl (1980), 44–47.
35. Garcia, P.L., Ebert, U., Frontiers of rapid itch relief: a review of methylprednisolone aceponate. J Eur Acad Dermatol Venereol 26:Suppl (2012), 9–13.
36. Schachner, L.A., Lamerson, C., Sheehan, M.P., et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics 116 (2005), e334–e342.
37. Callen, J., Chamlin, S., Eichenfield, L.F., et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 156 (2007), 203–221.
38. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 pharmacology review. 2000, Center for Drug Evaluation and Research, Silver Spring, MD Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50777_protopic.cfm. Accessed May 3, 2016.
39. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 pharmacology review. 2001, Center for Drug Evaluation and Research, Rockville, MD Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-302_Elidel.cfm. Accessed May 3, 2016.
40. Berth-Jones, J., Damstra, R.J., Golsch, S., et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ, 326, 2003, 1367.
41. Sobell, J.M., Foley, P., Toth, D., et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol 96 (2016), 514–520.
42. Stull, C., Lavery, M.J., Yosipovitch, G., Advances in therapeutic strategies for the treatment of pruritus. Expert Opin Pharmacother 1-17 (2015), 671–687.
43. Andoh, T., Yoshida, T., Kuraishi, Y., Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol 23 (2014), 359–361.
44. Wakita, H., Ohkuro, M., Ishii, N., Hishinuma, I., Shirato, M., A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fiber nerves. Exp Dermatol 24 (2015), 215–216.
45. Yosipovitch, G., Papoiu, A.D., What causes itch in atopic dermatitis?. Curr Allergy Asthma Rep 8 (2008), 306–311.